Oncolytics Biotech Inc. has entered into a clinical supply agreement with Coherus Oncology, Inc. to evaluate its investigational therapy, pelareorep, in combination with Coherus' PD-1 inhibitor, LOQTORZI, for treating squamous cell anal carcinoma (SCAC). This partnership is significant as it aims to address a critical gap in treatment options for patients who have progressed on current therapies. The study is expected to begin in the first quarter of 2027 at a premier cancer center in the United States.
Oncolytics Biotech Inc. is a clinical-stage immunotherapy company based in San Diego, California, specializing in the development of innovative cancer treatments. The company is listed on the Nasdaq under the ticker ONCY and is classified under the SIC code 2834, which pertains to pharmaceutical preparations. Recent filings include a 10-Q report filed on November 13, 2026, and several 8-K filings detailing various corporate events.
The SEC filing dated November 12, 2026, reveals that Oncolytics Biotech announced the clinical supply agreement on November 11, 2026. The agreement will facilitate a clinical study involving patients with SCAC, who have not responded to standard first-line treatments. The filing states, "This agreement supports a focused clinical evaluation of pelareorep with a marketed PD-1 inhibitor in a difficult-to-treat patient population," according to Jared Kelly, CEO of Oncolytics.
This partnership may significantly impact patients suffering from SCAC, as there are currently no approved therapies for second-line treatment in this indication. The study aims to evaluate the effectiveness of combining pelareorep with LOQTORZI, potentially enhancing antitumor immune responses and overcoming tumor immune resistance.
The filing does not specify what happens next, but the anticipated commencement of the study in early 2027 suggests further developments in this collaboration are on the horizon.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




